Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
– Results demonstrate melanocortin agonists may represent a new therapeutic avenue to treat diabetic nephropathy – Open Label Phase 2 clinical st...
– Results demonstrate melanocortin agonists may represent a new therapeutic avenue to treat diabetic nephropathy – Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J. , May 30, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of the poster " MC1R Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced Rat Model of Diabetic Nephropathy " at the International Podocyte Conference May 24-26, 2023 in Philadelphia, PA.